Literature DB >> 25696663

Antiplatelet therapy in patients undergoing coronary stenting: The risk of late stent thrombosis.

J M Ten Berg, J W van Werkum, A A C M Heestermans, W Jaarsma, R M A Hautvast, P den Heijer, M J de Boer.   

Abstract

BACKGROUND: Anticoagulation after coronary stenting is essential to prevent stent thrombosis. Drug-eluting stents, which are the preferred therapy, may be associated with a higher tendency for stent thrombosis.
METHODS: Patients who underwent coronary stent placement and presented with late stent thrombosis are described.
RESULTS: Eight patients with stent thrombosis are presented. Early discontinuation of the antithrombotic medication is associated with the occurrence of these complications.
CONCLUSION: Long-term antithrombotic therapy seems essential to prevent stent thrombosis, especially for patients treated with drug-eluting stents.

Entities:  

Keywords:  stents; thrombolytic therapy; thrombosis

Year:  2006        PMID: 25696663      PMCID: PMC2557282     

Source DB:  PubMed          Journal:  Neth Heart J        ISSN: 1568-5888            Impact factor:   2.380


  16 in total

1.  Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.

Authors:  D E Cutlip; D S Baim; K K Ho; J J Popma; A J Lansky; D J Cohen; J P Carrozza; M S Chauhan; O Rodriguez; R E Kuntz
Journal:  Circulation       Date:  2001-04-17       Impact factor: 29.690

2.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).

Authors:  M E Bertrand; H J Rupprecht; P Urban; A H Gershlick
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

3.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.

Authors:  Eugène P McFadden; Eugenio Stabile; Evelyn Regar; Edouard Cheneau; Andrew T L Ong; Timothy Kinnaird; William O Suddath; Neil J Weissman; Rebecca Torguson; Kenneth M Kent; August D Pichard; Lowell F Satler; Ron Waksman; Patrick W Serruys
Journal:  Lancet       Date:  2004 Oct 23-29       Impact factor: 79.321

4.  Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.

Authors:  Sean C Beinart; Paul Kolm; Emir Veledar; Zefeng Zhang; Elizabeth M Mahoney; Olivier Bouin; Sylvie Gabriel; Joseph Jackson; Roland Chen; Jaime Caro; Steven Steinhubl; Eric Topol; William S Weintraub
Journal:  J Am Coll Cardiol       Date:  2005-09-06       Impact factor: 24.094

5.  Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.

Authors:  Andrew T L Ong; Angela Hoye; Jiro Aoki; Carlos A G van Mieghem; Gaston A Rodriguez Granillo; Karel Sonnenschein; Evelyn Regar; Eugene P McFadden; Georgios Sianos; Willem J van der Giessen; Peter P T de Jaegere; Pim de Feyter; Ron T van Domburg; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

6.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

7.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

8.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

Authors:  Gregg W Stone; Stephen G Ellis; David A Cox; James Hermiller; Charles O'Shaughnessy; James Tift Mann; Mark Turco; Ronald Caputo; Patrick Bergin; Joel Greenberg; Jeffrey J Popma; Mary E Russell
Journal:  N Engl J Med       Date:  2004-01-15       Impact factor: 91.245

9.  Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.

Authors:  Muzaffer Degertekin; Patrick W Serruys; David P Foley; Kengo Tanabe; Evelyn Regar; Jeroen Vos; Peter C Smits; Wim J van der Giessen; Marcel van den Brand; Pim de Feyter; Jeffrey J Popma
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

View more
  1 in total

1.  Rapid oral desensitisation procedure in clopidogrel hypersensitivity.

Authors:  B Oppedijk; D A M Odekerken; J J van der Wildt; C F Melissant
Journal:  Neth Heart J       Date:  2008       Impact factor: 2.380

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.